证券代码：839729 证券简称：永顺生物 公告编号：2025-029 广东永顺生物制药股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 本次会议的参与表决监事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 1.议案内容： 根据《公司法》《公司章程》等有关规定，公司监事会对 2024 年度开展的工 作进行了总结回顾，编制了《2024 年度监事会工作报告》。 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出监事会会议通知的时间和方式：2025 年 4 月 15 日以书面方式发出 5.会议主持人：监事会主席梅双 6.召开情况 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-007 广东永顺生物制药股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 25 日 2.会议召开地点：广东省现代农业集团有限公司二楼会议室 3.会议召开方式：现场表决 4.发出董事会会议通知的时间和方式：2025 年 4 月 15 日以书面方式发出 5.会议主持人：董事长谭德明 6.会议列席人员：公司监事、公司高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的参与表决董事人数、召集、召开程序和议事内容均符合《公司法》、 《公司章程》及相关法律法规的规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 6 人，出席和授权出席董事 6 人。 二、议案审议情况 （一）审议通过《关于 2024 年度董事会工作报告的议案》 1.议案内容： 根据《公司章程》以及《董事会议事规则》的相关规定，公司董事会总结 ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-013 广东永顺生物制药股份有限公司 公司本次权益分派预案如下：公司目前总股本为 273,350,000 股，以未分配 利润向全体股东每 10 股派发现金红利 1.3 元（含税）。本次权益分派共预计派发 现金红利 35,535,500 元。 公司将以权益分派实施时股权登记日应分配股数为基数，如股权登记日应分 配股数与目前预计不一致的，公司将维持分派比例不变，并相应调整分派总额。 实际分派结果以中国证券登记结算有限责任公司北京分公司核算的结果为准。 二、最近三年现金分红情况 公司合并资产负债表、母公司资产负债表中本年末未分配利润为正值且报告 期内盈利，最近三年已分配及拟分配的现金红利总额（包括以现金为对价，采用 集中竞价方式、要约方式已实施的股份回购金额 28,801,567.63 元共计 188,473,174.35元，占最近三年年均归属于上市公司股东的净利润比例为306.75%, 超过 30%。 三、审议及表决情况 2024 年年度权益分派预案公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并 ...

Financial Performance - Net profit attributable to shareholders for Q1 2025 was ¥7,916,030.82, a decrease of 5.47% year-on-year[8]. - Operating revenue for Q1 2025 was ¥65,456,650.96, down 1.56% from ¥66,495,478.87 in Q1 2024[8]. - The net profit for the first quarter of 2025 is 7,916,030.82, a decrease of 5.48% compared to 8,374,511.51 in the same period of 2024[35]. - The total profit for the first quarter of 2025 is 8,711,054.06, down from 9,420,501.30 in the first quarter of 2024, representing a decline of 7.51%[35]. - The operating profit for the first quarter of 2025 is 8,718,430.12, slightly lower than 9,360,944.99 in the same period of 2024[35]. - Basic and diluted earnings per share remain unchanged at 0.03 for both the first quarter of 2025 and 2024[36]. - The total comprehensive income attributable to the parent company for the first quarter of 2025 is 7,916,030.82, compared to 8,374,511.51 in the first quarter of 2024[36]. Assets and Liabilities - Total assets as of March 31, 2025, reached ¥789,010,699.45, an increase of 3.76% compared to the end of the previous year[8]. - Current assets totaled CNY 601,207,705.58 as of March 31, 2025, up from CNY 564,818,676.77 at the end of 2024, reflecting a growth of 6.45%[31]. - Total assets increased to CNY 789,010,699.45 as of March 31, 2025, compared to CNY 760,429,656.42 at the end of 2024, marking a growth of 3.92%[32]. - Total liabilities rose to CNY 118,259,419.58 as of March 31, 2025, compared to CNY 99,800,423.50 at the end of 2024, indicating a significant increase of 18.43%[33]. - The total liabilities to assets ratio remained stable at 14.99% for both the parent and consolidated entities[8]. Cash Flow - The company's cash flow from operating activities increased by 3.35% to ¥17,062,453.70 compared to the same period last year[8]. - The cash flow from operating activities for the first quarter of 2025 is 17,062,453.70, an increase from 16,510,126.57 in the first quarter of 2024[36]. - The total cash outflow from operating activities in the first quarter of 2025 is 46,336,875.46, compared to 51,340,444.49 in the first quarter of 2024[36]. - The cash inflow from investment activities in the first quarter of 2025 is 120,362,370.26, significantly higher than 46,599,181.42 in the same period of 2024[36]. - The net cash flow from investment activities for the first quarter of 2025 is -46,677,987.64, compared to a positive 15,594,454.42 in the first quarter of 2024[37]. - Cash and cash equivalents decreased to CNY 22,468,586.94 from CNY 36,593,830.46, a decline of 38.67%[31]. - The cash and cash equivalents at the end of the first quarter of 2025 amount to 22,318,586.94, down from 205,772,155.39 at the end of the first quarter of 2024[37]. Shareholder Information - The largest shareholder, Guangdong Provincial Agricultural Group, holds 106,780,769 shares, accounting for 39.06% of the total shares[17]. - The second largest shareholder, Guangdong Agricultural Science Assets Management Co., Ltd., holds 53,872,000 shares, representing 19.71% of the total shares[17]. - The third largest shareholder, Guangdong Academy of Agricultural Sciences Animal Health Research Institute, holds 30,799,999 shares, which is 11.27% of the total shares[17]. - There are no pledges or judicial freezes on shares held by shareholders with more than 5% ownership[19]. - The company has no ongoing litigation, arbitration, or external guarantees during the reporting period[21]. - The company has fulfilled all previously disclosed commitments without any overdue situations[28]. Stock Information - The total number of unrestricted shares decreased from 80,425,041 to 76,825,041, representing a change of -3,600,000 shares, which is a reduction of approximately 4.48%[14]. - The total number of restricted shares increased from 192,924,959 to 196,524,959, reflecting an increase of 3,600,000 shares, which is an increase of about 1.87%[14]. - The total share capital remains unchanged at 273,350,000 shares[14]. - The company implemented a stock incentive plan in 2024, granting 3,600,000 restricted shares to 33 individuals, which is approximately 1.32% of the total share capital[24]. Expenses - The company's financial expenses increased by 89.18% to -¥107,316.35, primarily due to adjustments in financial product structures[10]. - Total operating costs for Q1 2025 were CNY 58,827,999.72, an increase of 2.19% from CNY 57,569,882.86 in Q1 2024[34]. - R&D expenses for Q1 2025 were CNY 5,153,474.56, slightly down from CNY 5,350,715.65 in Q1 2024[34]. - The company experienced a 337.53% increase in other payables, reaching ¥18,352,203.48, mainly due to equity incentive contributions[10]. - Non-recurring gains and losses for the period amounted to ¥2,535,421.70 after tax[12].

Financial Performance - The company's operating revenue for 2024 was CNY 268,985,086.87, a decrease of 14.41% compared to CNY 314,282,861.48 in 2023[22] - The net profit attributable to shareholders for 2024 was CNY 40,143,422.44, down 30.86% from CNY 58,058,744.25 in the previous year[22] - The gross profit margin for 2024 was 58.13%, slightly down from 58.82% in 2023[22] - The company's total revenue for the year was approximately ¥268.99 million, showing a slight decrease of 0.26% compared to the preliminary report[26] - The total profit amounted to approximately ¥44.51 million, reflecting a decline of 2.95% from the preliminary report[26] - The net profit attributable to shareholders was approximately ¥40.14 million, down by 2.74% compared to the preliminary report[26] - The net profit after deducting non-recurring gains and losses was approximately ¥30.99 million, a decrease of 4.17% from the preliminary report[26] - The company's operating revenue for 2024 was 268.99 million yuan, a decline of 14.41% from 314.28 million yuan in 2023, with a gross profit margin of 58.13%[62] - The net profit attributable to shareholders for the reporting period was 40.14 million yuan, down 30.86% from 58.06 million yuan in the previous year, mainly due to a decrease in operating profit and government subsidy income[64] Assets and Liabilities - Total assets at the end of 2024 amounted to CNY 760,429,656.42, a decrease of 3.48% from CNY 787,859,964.71 in 2023[23] - Total liabilities decreased by 16.35% to CNY 99,800,423.50 in 2024 from CNY 119,309,799.39 in 2023[23] - The company's total assets at the end of the reporting period were 760.43 million yuan, a decrease of 3.48% from the beginning of the period[40] - The company's cash and cash equivalents decreased by 77.33% to RMB 36.59 million, while other current assets increased by 89.15% to RMB 382.25 million[54] - The company's cash and cash equivalents at the end of the reporting period amounted to 36.59 million yuan, a decrease of 77.33% compared to the previous year-end of 161.40 million yuan, primarily due to adjustments in the structure of financial products held[57] Cash Flow - The company's cash flow from operating activities increased significantly by 133.52% to CNY 72,536,641.96 in 2024 compared to CNY 31,061,874.03 in 2023[23] - Net cash flow from operating activities increased by 133.52% year-on-year to ¥72,536,641.96[76] - Net cash flow from investing activities decreased by 90.13% year-on-year to -¥150,630,398.53, primarily due to increased investment in transferable certificates[77] Research and Development - Research and development expenses totaled 22.96 million yuan, accounting for 8.54% of operating revenue, with new veterinary drug registrations and clinical trial approvals obtained[42] - The company's R&D expenditure for the current period is ¥22,958,367.13, which represents 8.54% of operating revenue, an increase from 8.17% in the previous period[89] - The company has developed a new cell culture production technology for animal vaccines, which has received national invention patent authorization[32] - The company is developing multiple new veterinary vaccines, including a bivalent inactivated vaccine for swine influenza and a new vaccine for the prevention of hemorrhagic disease in freshwater fish[92][93] - The company has successfully developed a safe and effective inactivated vaccine for porcine epidemic diarrhea, with good immunogenicity and stability[95] Market Performance - Sales of pig live vaccines decreased by 19.92% year-on-year, while sales of poultry inactivated vaccines fell by 10.09%[41] - The company successfully registered 7 products in Vietnam and 2 in Egypt, with overseas revenue exceeding 20 million yuan, a year-on-year increase of 34.31%[44] - The average price of live pigs is projected to increase by 11.8% year-on-year to RMB 16.8 per kilogram in 2024, indicating a recovery in the industry[51] - The market share of non-mandatory immunization veterinary biological products is growing faster than that of mandatory immunization products, with pig biological products sales reaching RMB 7.154 billion in 2023[52] Governance and Management - The company has established a comprehensive governance structure including the shareholders' meeting, board of directors, supervisory board, independent directors, and specialized committees to ensure compliance and operational integrity[198] - The governance mechanism provides adequate protection and equal rights for all shareholders, with online voting options available for minority shareholders to facilitate participation[199] - The company has implemented a stock incentive plan in 2024, granting a total of 3.6 million restricted shares, accounting for approximately 1.32% of the total share capital of 27,335 million shares[149] - The stock incentive plan aims to attract and retain talent while enhancing the company's governance structure[148] - The company has recognized 28 individuals as core employees, aiming to optimize the long-term incentive mechanism[192] Risks and Challenges - The company faces uncertainties in funding for new projects, technology development, and product promotion, which could impact future growth[133][134] - The research and development of veterinary vaccines involves long cycles and high costs, with potential risks from rapid virus mutations affecting new product development[135] - The company's performance is closely tied to the livestock industry's health, with macroeconomic fluctuations and major disease outbreaks posing risks to operations[136] - The company is designated as a key producer of avian influenza vaccines, with sales primarily through government procurement, making it vulnerable to policy changes[137] Social Responsibility - The company has actively participated in rural revitalization efforts, providing high-quality products to farmers and donating CNY 10,000 to support university student volunteer programs[110] - The company has implemented a comprehensive environmental management system, ensuring compliance with national environmental regulations and standards[113] - The company has implemented measures to monitor and manage pollution emissions, with all monitoring data submitted to relevant authorities[114]

中信建投证券股份有限公司 关于广东永顺生物制药股份有限公司 2024 年募集资金存放与实际使用情况的专项核查意见 中信建投证券股份有限公司（以下简称："中信建投证券"、"保荐机构"）作 为广东永顺生物制药股份有限公司（以下简称"永顺生物"或"公司"）向不特 定合格投资者公开发行股票的保荐机构，根据《证券发行与承销管理办法》《北 京证券交易所股票上市规则（试行）》等相关规定，经审慎核查，对永顺生物 2024 年募集资金存放与实际使用情况发表核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可〔2020〕1271 号文核准，并经全国中 小企业股份转让系统有限责任公司同意，公司由主承销商中信建投证券股份有限 公司采用向不特定合格投资者公开发行方式发行人民币普通股（A 股）股票 1,200,000 股，每股面值 1 元，发行价为每股人民币 29.88 元，募集资金总额为 35,856,000.00 元，扣除发行权益性证券直接相关的新增费用 5,170,089.06 元后， 募集资金净额为 30,685,910.94 元。 天健会计师事务所（特殊普通合伙）对本次公 ...

（原标题：永顺生物换手率43.69%，龙虎榜上榜营业部合计净卖出1425.39万元） 永顺生物(839729)今日上涨7.08%，全天换手率43.69%，成交额3.95亿元，振幅24.28%。龙虎榜数据显示，营业部席位合计净卖出1425.39万元。 北交所公开信息显示，当日该股因日换手率达43.69%上榜，营业部席位合计净卖出1425.39万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交7760.05万元，其中，买入成交额为3167.33万元，卖出成交额为4592.72万元，合计 净卖出1425.39万元。 具体来看，今日上榜营业部中，第一大买入营业部为东方财富证券股份有限公司拉萨团结路第二证券营业部，买入金额为680.17万元，第一大卖 出营业部为中山证券有限责任公司广州花城大道证券营业部，卖出金额为1425.53万元。（数据宝） 永顺生物4月8日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 东方财富证券股份有限公司拉萨团结路第二证券营业部 | 680.17 | 285.96 | ...

证券代码：839729 证券简称:永顺生物 公告编号：2025-006 广东永顺生物制药股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 2 个有成交的交易日（2025 年 4 月 3 日至 2025 年 4 月 7 日）以内收盘价 涨幅偏离值累计达到 64.45%，根据《北京证券交易所交易规则（试行）》的有关规定，属于 股票交易异常波动情形。 二、公司关注并核实的相关情况 1、 核实对象： 公司控股股东、实际控制人及一致行动人、持股 5%以上股东，在任的董事、监事及高 级管理人员。 2、 核实方式： 电话询问、口头询问及微信询问等方式。 3、 核实结论： 前期公告的事项不存在需要更正、补充之处,未发现可能或已经对本公司股票交易价格 产生较大影响的媒体报道或市场传闻，不涉及热点概念事项；近期公司经营情况及内外部经 营环境未发生重大变化；公司、控股股东和实际控制人不存在关于本公司的应披露而未披露 的重大事项，或处于筹划阶段的重大事 ...

值得注意的是，回盛生物近8个交易日已累计大涨超170%。公司日前提示，关注到近期股吧等平台出现 关于泰乐菌素、泰万菌素价格波动的市场传闻。经核实，近期受市场供需关系因素影响，公司主要产品 泰乐菌素、泰万菌素产品的市场价格有波动。因产品价格波动的可持续性具有不确定性，如果未来市场 供给增加或需求减少，可能存在产品价格回落的风险，从而给公司业绩带来不利影响。 据悉，近期酒石酸泰乐菌素报价达290元/千克，创近两年价格峰值。该产品是治疗畜禽呼吸道疾病的关 键药物，市场需求受养殖业景气度回暖驱动。回盛生物现有泰乐菌素产能2000吨，技改完成后预计提升 至3000吨；泰万菌素产能840吨，市场份额占国内主导地位。公司联合科研机构研发新型替抗产品，并 推出多款宠物药品，包括驱虫药和耳道治疗软膏。 农业板块3日盘中强势拉升，动物保健股亮眼。截至发稿，永顺生物、美农生物（301156）、海利生物 （603718）、湘佳股份（002982）、金河生物（002688）、绿康生化（002868）等涨停，回盛生物 （300871）涨超14%，蔚蓝生物（603739）、晓鸣股份（300967）涨超5%。 此外，利民股份（002734） ...

证券代码：839729 证券简称：永顺生物 公告编号：2025-005 广东永顺生物制药股份有限公司 关于获得新兽药注册证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经中华人民共和国农业农 村部审查，批准广东永顺生物制药股份有限公司（以下简称"公司"）与其他单 位联合申报的"鸽新城疫灭活疫苗（P-VI株）"为新兽药，核发《新兽药注册证 书》，发布产品质量标准、工艺规程、说明书和标签，自发布之日起执行（农业 农村部公告第892号）。具体详情如下： 一、新兽药的基本信息 新兽药名称：鸽新城疫灭活疫苗（P-VI株） 新兽药注册证书号：（2025）新兽药证字19号 注册分类：二类 监测期：4年 主要成分与含量：疫苗中含灭活的重组鸽新城疫病毒 P-VI 株，病毒含量为 108.0EID50/0.1mL。 作用与用途：用于预防鸽的新城疫。接种后21日产生免疫力，30日龄以上鸽， 免疫期为3个月；30日龄鸽首免后，至4月龄或开产前加强免疫，免疫期为6个月。 二 ...